New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 8, 2022 - Novo Nordisk announced the launch of an authorized brand alternative (ABA) of its Tresiba (insulin degludec) injection.
Download PDF
Return to publications
